LimmaTech Biologics AG
Michael Kowarik is an accomplished professional in the fields of biochemistry and microbiology, currently serving as Chief Scientific Officer and Vice President of Business and IP Strategy at LimmaTech Biologics AG since August 2015. Previous roles include Head of Research and Group Leader at Glycovaxyn AG from October 2006 to July 2015, and Postdoctoral Fellow at ETH Zurich from 2003 to 2006. Michael Kowarik holds a PhD in Biochemistry and an MSc in Microbiology and Immunology, both obtained from ETH Zürich, with the PhD earned between 1999 and 2003 and the MSc completed between 1993 and 1998.
This person is not in any teams
LimmaTech Biologics AG
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.